Hair Loss Treatments That Work in 2026: The Current Evidence Landscape
The hair loss treatment landscape in 2026 looks meaningfully different from five years ago — three new drug approvals (for alopecia areata), one promising Phase 2/3 result for a new mechanism, and a growing evidence base for combination approaches. Here's the current state of what's available and what's coming.
01The proven foundation (still the best option for most people)
For androgenetic alopecia (pattern hair loss), the clinical baseline remains finasteride + minoxidil combination. The 2025 UK real-world study of 502 patients found 92% showed improvement on combination therapy — a real-world confirmation of what trial data has suggested for years. These two drugs, used together, remain the highest-evidence starting point.
02VDPHL01: the most significant pipeline news of 2026
Kintor Pharmaceutical's VDPHL01 (pyrilutamide) is a topical androgen receptor antagonist — it blocks DHT from binding to receptors at the scalp without systemic anti-androgen effects. In Phase 2/3 trials reported in April 2026, it outperformed topical minoxidil on hair count and shaft diameter at 24 weeks. It works through a fundamentally different mechanism than anything currently available. Subject to regulatory approval, it could represent a meaningful addition to the AGA toolkit.
Current topical options block either DHT production (topical finasteride) or promote growth (minoxidil). A topical androgen receptor blocker directly prevents DHT from reaching the receptor regardless of production levels — a different point of intervention that may be more complete for some patients.
03JAK inhibitors: the breakthrough for alopecia areata specifically
Three JAK inhibitors have been FDA-approved for severe alopecia areata: baricitinib (2022), ritlecitinib (2023), and deuruxolitinib (2024). These are specifically for the autoimmune type of hair loss — not for androgenetic alopecia. But for people with AA who had very limited options previously, these are genuinely transformative.
04What this means for you right now
If you have AGA and haven't started the evidence-backed foundation: the foundation is the right first step, and the 2026 data reinforces it. If you have AGA and have plateaued on the foundation: dutasteride escalation and topical finasteride options exist and work. If you have alopecia areata specifically: the JAK inhibitor conversation with a dermatologist is now relevant for severe cases.
Start with the strongest evidence base
Prescription finasteride + minoxidil — 92% response rate
Paid link Start your plan →Combination formulas and topical options
Paid link Get started →